EMA Recommends Valneva’s Chikungunya Vaccine for Use in Europe
The European Medicines Agency (EMA) has recommended Valneva’s single-dose chikungunya vaccine, Ixchiq, as the first preventive shot against the disease in Europe. With no approved drugs for chikungunya, the vaccine’s approval could be crucial in combating its spread in the region, especially with the increasing risks associated with climate change and global travel.
MHRA updates on study of risks associated with children born to men taking valproate
The Medicines and Healthcare products Regulatory Agency (MHRA) has provided an update on a new study regarding the risks associated with children born to men taking valproate. The new safety measures introduced in the UK are applicable to both male…